Relative ratios, seroconversion and proportion of patients attaining the median convalescent serum levels for SARS-CoV-2 antibodies after BNT162b2 or mRNA-1273 vaccination
| Weeks after second dose | Antibody | Relative ratio, median (IQR)* | No. (%) of patients with seroconversion† | No. (%) of patients who reached convalescent level‡ | |||
|---|---|---|---|---|---|---|---|
| BNT162b2 | mRNA-1273 | BNT162b2 | mRNA-1273 | BNT162b2 | mRNA-1273 | ||
| 6–7 | Anti-spike | 1.58 (1.28–1.67) | 1.72 (1.68–1.79) | 68 (97) n = 70 | 84 (97) n = 87 | 51 (73) n = 70 | 83 (95) n = 87 |
| Anti-RBD | 1.23 (0.61–1.64) | 1.44 (1.29–1.53) | 62 (89) n = 70 | 84 (97) n = 87 | 35 (50) n = 70 | 69 (79) n = 87 | |
| Anti-NP | – | – | 12 (17) n = 70 | 10 (12) n = 87 | 6 (9) n = 70 | 4 (5) n = 87 | |
| 12 | Anti-spike | 1.45 (1.09–1.58) | 1.93 (1.76–2.02) | 117 (95.9) n = 122 | 68 (96) n = 71 | 70 (57.4) n = 122 | 68 (96) n = 71 |
| Anti-RBD | 0.89 (0.36–1.43) | 1.32 (1.04–1.47) | 107 (87.7) n = 122 | 67 (94) n = 71 | 47 (38.5) n = 122 | 45 (63) n = 71 | |
| Anti-NP | – | – | 14 (11.5) n = 122 | 4 (6) n = 71 | 7 (5.7) n = 122 | 2 (3) n = 71 | |
Note: IQR = interquartile range, NP = nucleocapsid protein, RBD = receptor binding domain.
↵* We did not report summary statistics for anti-NP because it was used as a binary measure of natural SARS-CoV-2 infection.
↵† Antibody levels are reported as relative ratios to synthetic standards. Seroconversion threshold levels represented a positive test and were 0.19, 0.186 and 0.396 for anti-spike, anti-RBD and anti-NP antibodies, respectively.
↵‡ The median level of antigen in convalescent serum was from a cohort of 211 patients in the general population with previous COVID-19 of all severities and represented a robust antibody response: 1.38, 1.25 and 1.13 for anti-spike, anti-RBD and anti-NP antibodies, respectively.